Bioequivalence of a hybrid pegylated liposomal doxorubicin hydrochloride injection and Caelyx®: A single-dose, randomized, multicenter, open-label, two-period crossover study in patients with advanced ovarian cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Prakash S,S

第一单位： Department of General Surgery, MMC and RI, K.R. Hospital, Mysore, Karnataka, India.

作者： Prakash S,S ^[1] ; Rajnish Vasant,Nagarkar ^[2] ; Krishna Chaitanya,Puligundla ^[3] ; Lokesh K,N ^[4] ; Rakesh Reddy,Boya ^[5] ; Ankit Baldevbhai,Patel ^[6] ; Lovenish,Goyal ^[7] ; Aniket,Thoke ^[8] ; Jigar Gordhanbhai,Patel ^[9] ; Ajay Omprakash,Mehta ^[10] ; Ghanshyam Nanubhai,Patel ^[11] ; Mujtaba A,Khan ^[12] ; Imran,Ahmad ^[13]

作者单位： Department of General Surgery, MMC and RI, K.R. Hospital, Mysore, Karnataka, India. ^[1] Curie Manavata Cancer Centre, Nashik, Maharashtra, India. ^[2] Department of Medical Oncology, MNJ Institute of Oncology & RCC, Hyderabad, Telangana, India. ^[3] Oncolgy Department, Shetty's Hospital, Bommanahalli, Bangalore, Karnataka, India. ^[4] Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam, Andhra Pradesh, India. ^[5] Unique Hospital - Multispeciality & Research Institute, Surat, Gujarat, India. ^[6] Aadhar Health Institute, Tosham Road, Hisar, Haryana, India. ^[7] Sanjeevani CBCC USA Cancer Hospital, Raipur, Chhattisgarh, India. ^[8] Aman Hospital and Research Center, Vadodara, Gujarat, India. ^[9] HCG NCHRI Cancer Centre, Nagpur, Maharashtra, India. ^[10] Nirmal Hospital Pvt. Ltd., Surat, Gujarat, India. ^[11] Intas Pharmaceuticals Limited, Ahmedabad, Gujarat, India. ^[12] Jina Pharmaceuticals Inc., Libertyville, IL, USA. Electronic address: imran@jinapharma.com. ^[13]

关键词 Doxorubicin Hybrid Liposomal Ovarian cancer Pegylated